Technology Platforms   AC Immune's R&D program is based upon two platform technologies. Both platforms lead to new classes of therapies that address conformational diseases such as Alzheimer's disease where conformational changes of proteins are ultimately linked to the disease.
	» Technology Platforms » Product Pipeline » Target Markets		AC Immune's first supramolecular antigen platform technology brings the ability to break the immune tolerance to "self" proteins by generating conformation-sensitive antibodies that lead to the creation of active and passive immune therapies. The second platform focuses on the chemistry of small molecules, Morphomers™. Morphomers™ are non-covalent complexes of small molecules with particular sequences of the target proteins. They occur in different conformational states and create drugs capable of targeting and modifying the conformational state of targeted proteins and render them harmless.   Both platforms lead to new classes of therapies that "break" the pathological ß-sheet conformation of proteins by shifting the equilibrium via stabilization of the soluble form (non-pathological form) of the protein target.		A) Supramolecular constructs improve antigen presentation and conformation sensitivity of the elicited antibodies. As a consequence higher antigenicity and affinity is achieved. B) Morphomers™, β-sheet breakers: non-covalent complexes of small molecules formed with protein sequences in different conformations for which they show different affinities.